Science Advances presented a distinction between regulated and protected growth arrest and disordered and unstable arrest, with a weak point in the cell envelope that may allow for targeted treatment strategies.
Antibiotics are supposed to kill bacteria. In fact, in resistant infections, a small proportion of cells survive even without resistance mutations. After treatment is over, those cells can “wake up” and cause a relapse. This phenomenon is called persistence (antibiotic persistence), and is one of the reasons why some infections recur despite treatment that seems correct on paper.
A new study from the Hebrew University, published inScience Advances, offers a simple explanation that settles long-standing debates in the field: Not all “persistence cells” are alike. In fact, bacteria can achieve high survival under antibiotics through Two completely different growth arrest statesThe difference between them is not just theoretical. It changes the question of which treatment or drug combination might work.
Not just hibernation: “protected” stopping versus “disrupted” stopping
For years, the dominant explanation was simple: the bacteria enter a controlled dormancy. Many antibiotics primarily harm cells that are growing and dividing. Therefore, an “old” cell is less damaged.
The new study agrees that this happens, but adds another pathway. According to the authors, high survival can result from two “archetypes” of growth arrest:
One is Regulated stop which brings about a dormant and protected state. The second is Disturbed and unregulated stopping. This is an unstable state. The cell is not “silently defending itself,” but rather is entering a state of dysfunction. This is precisely where potential weaknesses lie, especially in the context of the stability of the cell envelope.
How did they show that there are two different situations here?
The team worked mainly with E. coli And compare two ways to bring a culture to growth arrest.
In one condition, the bacteria naturally reached a stage where they ran out of nutrients. In the other condition, they were subjected to a sharp stress that simulated sudden starvation using serine hydroxamate (SHX)In both cases, when the bacteria entered a halt and were then exposed to a beta-lactam antibiotic (such as ampicillin), it was seen High tolerance and similarBut from here on, profound differences emerged.
To differentiate between the situations, the researchers combined mathematical models with several experimental tools:
Transcriptomics to see which genes are “turned on” under stress, microcalorimetry to measure tiny heats that indicate metabolic activity, and microfluidics to track individual cells over time. This combination showed that “regulated arrest” tends to be more stable and uniform across cells, while “disordered arrest” is characterized by high variability and less controlled dynamics.
One of the most striking findings: in the disturbed state, the bacteria showed General disruption of the cell membrane balance (membrane homeostasis). This is not another “little feature.” This is a weak point that can become a therapeutic target.
Why this could change treatment
The study does not propose a new antibiotic for the shelf, but it does suggest a way to think about strategy. If some of the survivors are “protected dormant,” it may be worth trying to get them out of a controlled arrest and then attack them, for example by using conditions that encourage regrowth along with appropriate antibiotics. On the other hand, if some are in a disturbed state where the cell envelope is unstable, it may be better to attack membrane weaknesses or choose combinations that exploit this disruption.
The EurekAlert announcement accompanying the publication emphasizes that the division into two “survival states” could explain why various studies in the field have previously obtained conflicting results. Sometimes they simply studied different physiological states without calling them by different names.
It is important to say this with caution: this is a framework that connects mechanism, measurement, and therapeutic proposal. The transition to real infections in the body and clinical protocols is the next step, and is not directly examined here.
More of the topic in Hayadan:
